Orquest

Clinical studies of firm's Ossigel bone growth factor will begin the third quarter of 2001 to support a PMA submission in early 2003. Orquest is currently completing a feasibility study in the U.S., while a 140-patient study is under way in Europe to evaluate Ossigel's performance in healing fresh fractures. The company emphasizes that it is the sole developer of the product, and that it maintains a manufacturing contract with Anika Therapeutics. "The Gray Sheet" (Jan. 22, 2001, p. 15) had suggested that Ossigel is being jointly developed